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Abstract
Micro-ribonucleic acids (microRNAs) are small molecules containing 20-23 nucleotides. Despite their small size, it is likely 
that almost every cellular process is regulated by them. Moreover, aberrant microRNA expression has been involved in the 
development of various diseases, including cancer. Although many data are available about the role of microRNAs in various 
lymphoproliferative disorders, their impact on the development of acute lymphoblastic leukemia of T-cell progenitors is largely 
unknown. In this review, we present recent information about how specific microRNAs are expressed and regulated during 
malignant T-lymphopoiesis and about their role during normal hematopoiesis. 
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For more than 50 years the term “gene” has been syn-
onymous of genomic regions encoding messenger RNAs 
(mRNAs). However, recent studies have demonstrated that 
the entire genome gives rise not only to mRNAs but also 
to thousands of small regulatory RNAs, the so-called non-
coding micro RNAs (microRNAs) (1). The first microRNA 
was described by the group of V. Ambros in the nematode 
Caenorhabditis elegans and was named lin-4 (2). Five years 
later, in 1998, the process of RNA interference (silencing of 
specific genes) carried out by microRNAs was described in 
plants (3,4). Subsequently, it was assumed that microRNAs 
regulate gene expression at the post-transcriptional level 
in presumably every multicellular organism (5). At pres-
ent, it is clear that more than 3% of human genes encode 
microRNAs, regulating approximately 90% of the protein-
coding genes (6). 
microRNAs consist of small molecules containing 
20-23 nucleotides (nt) and function most frequently as 
negative regulators of gene expression. They exert their 
effects post-transcriptionally by inhibiting mRNA transla-
tion or inducing mRNA degradation, and thus participate 
in a wide variety of physiological and pathological cellular 
functions (7). microRNAs are now among the most studied 
non-coding RNAs and it is not an exaggeration to say that 
their identification opened a new era in cancer research. 
Over the past few years, molecular oncology research has 
revealed that abnormalities in both protein-coding genes 
and microRNAs can be identified in tumors and that the 
interplay between proteins and microRNAs is involved in 
the initiation, progression, and metastasis of various types 
of human cancer (8). Such malignancies include brain, liver, 
prostate, ovarian, and oral cancer, as well as lymphomas, but 
this list is probably much longer (9-14). Aberrant microRNA 
expression could also play a vital role in the pathogenesis 
of leukemia and thus microRNAs have rapidly emerged as 
potential targets for anti-leukemia therapy (10). 
This review focuses on recent information about the im-
portant roles of microRNAs during the normal hematopoietic 
development as well as their implications during the progress 
of leukemia and more specifically of T-cell malignancies. 
Biogenesis and cellular functions of 
microRNAs
microRNAs are encoded within different genomic 
regions including protein-coding genes and non-coding 
transcription units. Approximately 50% of all synthesized 
microRNAs are derived from non-coding RNA transcripts, 
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while an additional ~40% are located at introns of the 
protein-coding genes. The majority of microRNAs are 
transcribed by RNA polymerase II (RNA pol II) and bear a 
7-methyl guanidine cap at the 5’-end of the molecule and 
a poly-adenine (poly-A) tail at its 3’ end (15). 
The mechanism giving rise to mature microRNAs in-
volves two processing cleavages by the RNAse III enzymes 
Drosha and Dicer. Following transcription by RNA pol II, 
Drosha processes the primary microRNA transcript (pri-
microRNA) into ~60-100-nt hairpin structure designated as 
precursor RNA (pre-microRNA). Through interaction with 
exportin-5 and Ran-GTP, the pre-microRNA is transported 
into the cytoplasm, where it is processed de novo by the 
catalytic activity of Dicer. This ultimate cleavage gives rise 
to a double-stranded ~20-23-nt product, which consists of 
a mature microRNA guide strand and a passenger strand 
(microRNA*). The mature microRNA is then loaded into ef-
fector complexes known as RNA-induced silencing complex, 
while the passenger strand is degraded (16). 
microRNAs inhibit gene expression by binding to the 
complementary 3’ untranslated region (3’UTR) of the target 
messenger RNA. Every organism synthesizes hundreds of 
unique microRNAs, each predicted to regulate specific target 
genes. Moreover, nearly all microRNAs identified in humans, 
plants and animals are evolutionary conserved (17). 
Functions of microRNA in normal 
hematopoiesis
 
Hematopoiesis is sustained by continuous differen-
tiation of multipotent hematopoietic stem cells (HSCs) 
into hematopoietic progenitor cells (HPCs), giving rise to 
different lineages and mature blood cells. Regulation of 
hematopoiesis consists of two aspects: self-renewal of 
HSCs (progressive restriction of lineage potential) and dif-
ferentiation of HSCs/HPCs (development into differentiated 
precursors up to mature cells). HSC differentiation leads 
to the formation of multipotent cells, which have largely 
lost their capacity for self-renewal, but retain the ability to 
differentiate into many types of blood cells. These HPCs 
generate common lymphoid progenitors, giving rise to 
B- and T-lymphocytes, and common myeloid progenitors, 
generating erythrocytes, megakaryocytes, granulocytes, 
and monocytes/macrophages (Figure 1) (18).
microRNAs are differentially expressed during normal 
hematopoiesis (Figure 1). Chen et al. (19) were the first 
to report that microRNAs are specifically expressed and 
dynamically regulated during murine hematopoietic cell 
development (19). Since that report, several groups have 
used different techniques to isolate progenitors, to induce 
uni- or multilineage differentiation, and to describe the mi-
croRNA expression profile and/or function during murine 
and human hematopoiesis.
During human erythropoiesis, microRNA-221 and mi-
croRNA-222 are highly expressed in CD34+ HPCs and are 
gradually down-modulated during unilineage erythroid differ-
entiation. The decline of microRNA-221 and microRNA-222 
expression during the exponential erythroid growth unblocks 
c-kit protein translation. Since c-kit is a receptor of the kit 
ligand or stem cell factor, this can lead to expansion of early 
erythroblasts (20). Two additional pathways essential for 
erythropoiesis are also modulated by microRNAs: ALK4 and 
GATA-1. MicroRNA-24 is a negative regulator that inhibits 
erythroid differentiation by targeting active type I receptor 
ALK4 (21). The second pathway is a globin transcription 
factor 1 (GATA-1-regulated microRNA locus, consisting of 
microRNA-144 and microRNA-451, which regulates eryth-
roid development in zebrafish embryos (22).
With respect to the common erythrocyte-megakaryocyte 
precursors, microRNA-150 was found to drive in vitro and 
in vivo megakaryocytic differentiation at the expense of the 
erythroid lineage (23). Furthermore, a regulatory pathway in 
megakaryocytopoiesis involving the promyelocytic leukemia 
zinc finger (PLZF) transcription factor, microRNA-146a and 
the stromal-cell-derived factor 1 receptor CXCR4 has been 
identified. microRNA-146a was initially reported to be an 
endotoxin-responsive gene in human monocytes. PLZF pro-
tein is a transcription factor that is involved in the regulation 
of limb and skeleton formation, hematopoietic proliferation 
and differentiation, leukemogenesis, and tumorigenesis. 
In this recently identified pathway, PLZF transcriptionally 
inhibits microRNA-146a, which in turn regulates the CXCR4 
co-receptor. In CD34+ HPC megakaryopoietic cultures, 
PLZF was up-regulated, a fact leading to a decrease of 
microRNA-146a expression and to increased levels of 
CXCR4 protein. MicroRNA-146a overexpression as well 
as PLZF or CXCR4 silencing impaired megakaryocyte 
proliferation, differentiation, maturation, and colony forma-
tion (24-26).
The key role of microRNAs was also demonstrated in hu-
man monocytopoiesis by two separate studies (27). The first 
examined the role of microRNAs of the 17-5p-92 and 106a-
92 clusters in monocytic differentiation (28). The microRNA-
17-5p-92 cluster consists of seven microRNAs located on 
chromosome 13 and transcribed as a polycistronic unit (15). 
This cluster is highly homologous to the microRNA-106a-92 
and microRNA-106b-25 clusters located on chromosomes 
Y and 7, respectively (29). During monocytic differentiation, 
low levels of microRNA-17-5p/20a/106a allow translation 
of acute myeloid leukemia 1 (AML1) transcription factor 
that inhibits microRNA-17-5p-92 and microRNA-106a-92 
clusters. It also trans-activates the expression of monocyte 
colony-stimulating factor (M-CSF), thus inducing monocytic 
cell differentiation. This study indicates that monocytopoiesis 
is controlled by a circuitry sequentially involving microRNA-
17-5p/20a/106a, AML1 and M-CSF receptor, whereby 
microRNA-17-5p/20a/106a functions as a gene complex 
interlinked with AML1 in a mutual negative-feedback loop 
(27). Interestingly, the microRNA-17-92 cluster is also es-
sential for B-lymphocyte development in vivo. Its targeted 
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deletion in mice resulted in lung hypoplasia and inhibition 
of the pro-B to pre-B transition (30). On the other hand, 
transgenic expression of microRNA-17-92 in mice caused 
the development of lymphoproliferative diseases and au-
toimmunity disorders (31).
Additional microRNAs are also involved in the PU.1-
dependent regulatory pathway, which is required for normal 
human monocytic differentiation (28). It was found that 
the master transcription factor PU.1 directly activates mi-
croRNA-424 transcription during monocytic differentiation 
of promyelocytic blasts as well as human HPCs in unilin-
eage monocyte cultures. microRNA-424 was found to be 
a potent inducer of monocyte differentiation, particularly by 
targeting the transcription nuclear factor I-A (NFI-A), whose 
down-regulation is critical for the progression to monocytic 
differentiation (28).
microRNAs have also been linked to macrophage 
functions during inflammation and development of innate 
immunity. microRNA-155 was found to be up-regulated in 
primary murine macrophages after exposure to interferon β 
and poly(I:C) (32). Sustained expression of microRNA-155 in 
HSCs causes abnormal proliferation of myeloid cells (33). 
During myelopoiesis, microRNA-223 levels rise 
progressively and their suppression blocks granulocytic 
maturation. The levels of microRNA-233 are modulated by 
competitive binding to its upstream part of two CCAAT-box-
binding proteins: NFI-A and C/EPBα. These two proteins 
bind to the CAAT elements located on the pre-microRNA 
promoter. NFI-A maintains microRNA-223 at low levels, 
while its replacement by C/EPBα activation results in mi-
croRNA-223 up-regulation and granulocytic differentiation 
(34). The transcriptional induction of the myeloid-specific 
microRNA-223 is responsible for granulocyte-monocyte 
precursor progenitor proliferation and granulocyte function 
in vivo (35,36). 
microRNA expression and significance during 
normal and malignant T-lymphopoiesis
The earliest progenitors of T-lymphocytes are derived 
Figure 1. Role of microRNAs in normal hematopoiesis. The figure shows the microRNAs involved in, and their expression during the 
hematopoiesis and differentiation of MPP cells into different lineages. Red and green color indicates microRNAs that are overexpressed 
and underexpressed, respectively. MPP = multipotent progenitor cell; CLP = common lymphoid progenitor; DN = double negative; DP 
= double positive; Th1 = T-helper 1; Th2 = T-helper 2; CMP = common myeloid progenitor; GMP = granulocyte-monocyte precursor; 
GP = granulocyte precursor; G = granulocyte; MP = monocyte-macrophage precursor; Mo = monocyte; Ma = macrophage; EMP 
= erythrocyte-megakaryocyte precursor; EP = erythrocyte precursor; E = erythrocyte; MgP = megakaryocyte precursor; Pl = platelets. 
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from the bone marrow. They are extremely rare and typically 
are present within complex populations of hematopoietic 
stem cells (37). Although they are generated within the bone 
marrow, most of T-cell development occurs in a special-
ized organ, i.e., the thymus. These distinct differentiation 
compartments underscore the unique capacity of the thymic 
microenvironment to support T-cell lineage restriction and 
differentiation. The development of T-lymphocytes is sup-
ported by many thymus-derived signals such as Notch, 
morphogenetic, and protein kinase signals (38). The devel-
opment of T cells in the thymus as well as their activation at 
the periphery, are controlled by complex protein signaling 
pathways that are regulated by the microRNAs. Expression 
profiles of these microRNAs vary during the different stages 
of T cell and cellular subset development. Two specific mi-
croRNAs, microRNA-17-92 and microRNA-155, have been 
implicated in T-cell development and probably account for 
some of the phenotype of Dicer deficiency in T cells. Recent 
data also indicate a role of microRNAs in the differentiation 
of T cells into different effector T-helper cell subsets. For 
example, in microRNA-155-deficient mice, T cells develop 
directly into Th2 cells, which indicate that microRNA-155 
regulates the differentiation into Th type 1 cells. Also, mice 
with conditional deletion of Dicer or Drosha in regulatory T 
cells (Treg) show requirement for the microRNA pathway 
in forkhead boxP3+ Treg cells. These animals develop a 
lethal autoimmune inflammatory disease accompanied by 
impaired development and function of Treg cells (39). More-
over, mice lacking microRNA-155 were immunodeficient 
and displayed increased lung airway remodeling due to the 
impaired functions of B- and T-lymphocytes and dendritic 
cells (40). The development of T cells and the regulatory 
role of microRNAs is described in Figure 2 (41). 
Recent data suggest that microRNA genes are new 
epigenetic targets in cancer development. Their altered 
regulation by oncogenic proteins and more specifically by 
fusion proteins expressed during hematological malignan-
cies is potentially relevant to the pathogenesis of leukemic 
diseases. Numerous oncogenes and tumor suppressor 
genes are potentially regulated by microRNAs (42). mi-
croRNAs may play a role in oncogenesis as oncogenes, 
probably by variety of mechanisms involving the elimination 
Figure 2. Schematic diagram of T-cell development and regulation and the participation of microRNAs in its regulation. HSC = he-
matopoietic stem cell; MMP = multipotent progenitor cell; CLP = common lymphoid precursors; DN thymocyte = double-negative 
thymocyte; DP thymocyte = double-positive thymocyte; SP thymocyte = single-positive thymocyte. (Reproduced from Ref. 41, with 
permission from Macmillian Publishers Ltd.).
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of tumor suppressor proteins or suppression of genes by 
targeting oncogenic mRNAs (43). 
microRNA-mediated tumorigenesis may result from 
either down-regulation of tumor suppressor genes or up-
regulation of oncogenes. Usually microRNA genes are 
located at fragile sites of the genome as well as in minimal 
regions with loss of heterozygosity, regions of amplification 
(minimal amplicons) or common breakpoint regions (42). 
The aberrant expression at such sites has been associ-
ated with solid tumors and hematopoietic malignancies, as 
suggested by the following examples: frequent deletion of 
microRNA-15a and microRNA-16-1 in chronic lymphocytic 
leukemia, increased levels of microRNA-155 in diffuse large 
B-cell lymphomas, and increased levels of microRNA-181 
in acute myeloid leukemia (AML) types M1 and M2 (43). 
Besides, aberrancies of the normal microRNome have 
been well documented in almost all hematological malig-
nancies, suggesting in most cases the so-called specific 
microRNA-signatures. Also of importance is the fact that 
some of the microRNA-expression abnormalities described 
in leukemias and lymphomas can be interpreted on the 
basis of the microRNome variations during normal hema-
tologic ontogenesis. This suggests that their origin is from 
a particular differentiation stage in which the hematopoietic 
differentiation is “frozen” in the malignancy (44).
Acute lymphoblastic leukemia (ALL) is a genetically het-
erogeneous lymphoid malignancy, which may involve B or 
T lineages, and leukemic cells may present immunopheno-
typic markers characteristic of distinct stages of maturation 
(45-47). The quantitative and qualitative differences in the 
expression of these markers are useful for the diagnosis, 
classification and prognostic stratification of patients with 
ALL (47). Moreover, there are geographic differences in 
the distribution of ALL subtypes (48,49). In addition to im-
munophenotypic markers, ALL is characterized by various 
underlying genetic abnormalities. Zanette et al. (50) have 
compared the profile of microRNA expression in CD19+ 
cells from patients with ALL of B-progenitors with CD19+ 
cells from the peripheral blood of healthy subjects. The five 
most highly expressed microRNAs in ALL were microRNA-
128b, microRNA-204, microRNA-218, microRNA-331, and 
microRNA-181b-1. The most represented microRNA in ALL 
is microRNA-128b with more than a 400-fold difference 
compared to normal CD19+ B cells. microRNA-128b is a 
reported homologue of microRNA-128a and has been found 
in colon, lung, and pancreas solid cancers. On the other 
hand, the four microRNAs with the lowest expression levels 
were microRNA-135b, microRNA-132, microRNA-199s, 
microRNA-139, and microRNA-150 (50). 
More recently, Mi et al. (51) performed a large-scale 
genome-wide microRNA expression profiling assay and 
identified 27 microRNAs that are differentially expressed 
between ALL and AML. Using expression signatures of at 
least two of these microRNAs results in an accuracy rate 
of >95% in distinguishing and diagnosing AML and ALL. 
Among these microRNAs differentially expressed between 
ALL and AML, microRNA-128a, microRNA-128b, let-7b, and 
microRNA-233 were most significantly distinct. microRNAs 
128a and 128b were expressed at higher levels in ALL, 
whereas microRNAs 233 and let-7b were expressed pre-
dominantly in AML. microRNA-233 is also reported to be a 
“myeloid” gene that plays a critical role in myeloid functions 
and differentiation (51). 
Interestingly, a special microRNA expression profile was 
recently identified in children experiencing ALL relapse, 
which was characterized by high levels of expression of 
microRNA-7, microRNA-198 and microRNA-663 and low 
levels of microRNA-126, microRNA-222, microRNA-551a, 
microRNA-345. Nevertheless, the mechanisms involved in 
the regulation of these microRNAs have not been identified. 
This “cascade” of microRNAs was also identified in samples 
of ALL with subsequent central nervous system relapse, 
suggesting they may serve as biomarkers in the detection 
of early central nervous system relapse of pediatric ALL. 
Interestingly, target prediction of the microRNA pattern 
revealed that some abnormally expressed microRNAs may 
putatively target neuron function- and neurotransmitter-
related genes (52). 
The prognostic value of microRNAs in ALL is further 
demonstrated by the significance of microRNA-16. In gen-
eral, low levels of microRNA-16 expression are associated 
with better outcome, while higher expression levels of this 
microRNA are associated with the poorest type of prognosis. 
This microRNA functions by inhibiting cell cycle progression 
by targeting several cyclins (E, D1), CDK6 and by inducing 
apoptosis by inhibiting BCL-2 translation. Considering these 
main functions of microRNA-16, the poor prognosis associ-
ated with its higher expression levels in ALL is astonishing. 
In this respect, researchers have failed to demonstrate a 
relationship between microRNA-16 expression and malig-
nant lymphocyte proliferation or differentiation. However, 
investigation of the extent to which microRNA-16 varies 
within normal peripheral blood leukocyte stimulation, has 
revealed that its decrease after stimulation is necessary 
for the induction of lymphocyte proliferation. In contrast, a 
microRNA-16 increase might act as a restriction point in the 
entire proliferation process. Thus, microRNA-16 expression 
levels appear to be of prognostic significance in ALL, which 
may be controlled in independent and larger series (53). 
We have recently studied the microRNA expression 
profile in a subgroup of patients with T-ALL, associated with 
a poor prognosis: T-ALL expressing NK markers (CD56 or 
N-CAM) (54,55). By multiple comparisons, we determined 
the microRNA expression profile of normal CD3+/CD56- and 
CD3-/CD56+ cells and of T-ALL/CD56+ and T-ALL/CD56- 
leukemic samples. Hierarchical cluster analysis revealed 
that normal and leukemic samples were grouped into two 
distinct clusters. The expression of 95 of 157 (60.5%) 
microRNAs did not differ from that of endogenous RNAs. 
Most of the differentially expressed microRNAs were less 
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in human ALL cells and the enforced expression of the 
microRNA-22 gene can inhibit the in vivo growth of B-cell 
lymphomas in mice, indicating the anti-tumor effect of 
microRNA-22. Moreover, histone modifications have been 
implicated in various cancers and histone deacetylase activ-
ity inhibitors possess significant growth inhibitory activity 
on ALL cells. For further research activities it would be of 
interest to investigate the functional role of microRNA-22 
in histone modification associated with tumor initiation, 
promotion and progression of leukemia cells (57).
The regulation of microRNA expression is documented 
in cells infected with human retroviruses. Human T-cell 
leukemia virus type-1 (HTLV-1) is a causative agent of adult 
T-cell leukemia, which is an aggressive CD4+ malignancy. 
Tomita et al. (58) discovered that the expression of selected 
microRNAs and especially microRNA-146a is altered in 
HTLV-1-infected T-cell lines compared to uninfected cells. 
MicroRNA-146a is one of the key molecules in the inflam-
matory response and its expression is induced by activation 
by the NF-κB signaling pathway. It is expressed in HTLV-
1-infected T-cell lines and is induced directly by the virus-
encoded transactivator protein tax that plays a central role 
in viral pathogenecity. Exactly how the tax-microRNA-146a 
relationship regulates cell growth is difficult to determine, but 
it probably has several targets including IRAK 1, TRAF-6, 
IL-8, CXCR4, and matrix metalloproteinase 9. Thus, iden-
tification of aberrant expression of specific microRNAs in 
HTLV-1-infected cells may reveal novel retroviral functions 
in the pathogenesis of latent HTLV-1 infection. In the future, 
microRNAs could be used in clinical studies to predict the 
development of HTLV-1 leukemogenesis. Inhibition of 
microRNA-146a by anti-microRNA inhibitors suppresses 
the proliferation of HTLV-1-infected T-cell lines but, on the 
other hand, uninfected cell lines proliferate rapidly. These 
data suggest that microRNA-146a might be a promising 
therapeutic target in adult T-cell leukemia (58). 
In conclusion, microRNAs are key regulators of cellu-
lar differentiation and their aberrant expression has been 
associated with the characteristic block of T-cell differen-
tiation in T-ALL. Moreover, differential synthesis of some 
microRNAs has proved to be a prognostic factor for the 
outcome of ALL and/or could be used for its diagnosis. As a 
matter of fact, analysis of microRNA expression may prove 
to be of greater clinical significance than mRNA profiling, 
in contrast to mRNA expression, for a small number of 
microRNAs might be sufficient to classify human leukemias 
and, unlike mRNAs, microRNAs remain intact in routinely 
collected formalin-fixed or paraffin-embedded clinical tis-
sues. Nevertheless, this assumption still requires extensive 
independent studies to be conducted before microRNA 
analysis is introduced into routine clinical exams. 
expressed in leukemic cells than in normal cells. microRNA-
29b was significantly more expressed in leukemic cells 
than in normal cells. By contrast, microRNA-223 was less 
expressed in these comparisons. Known targets include 
the TCL1 and MCL1 genes for the former and NFIA-1 for 
the latter. Interestingly, the relevance of microRNA-223 to 
hematopoietic differentiation has been demonstrated in 
myelopoiesis, where there is a direct correlation between the 
transcriptional and epigenetic regulation of microRNA-223 
(34-36).
In our study (54), microRNA-152 was less expressed 
in leukemic blasts compared to normal cells; however, 
within the latter, microRNA-152 was more expressed in 
CD3-/CD56+ than in CD3+/CD56- cells. microRNA-181a 
and microRNA-181b were more expressed in T-ALL/CD56- 
cells than in CD3+/CD56- cells, whereas microRNA-374 
was more expressed in T-ALL/CD56+ cells than in CD3+/
CD56- and CD3-/CD56+ cells. Comparison between T-ALL/
CD56+ and T-ALL/CD56- cells demonstrated a 270-fold 
increase in microRNA-221 expression in the former. Among 
the microRNA-221 targets are p27/kip1, an important cell 
cycle regulator, and the c-kit receptor from the tyrosine 
kinase family, which have constitutively augmented activity 
in other hematological malignancies. 
Mi et al. (56) have demonstrated that microRNAs-17-92 
could play an essential role in the development of mixed 
lineage leukemia (MLL)-rearranged acute leukemia. This 
cluster was highly expressed not only in MLL-associated 
AML but also in ALL. The amplification of 13q31 and up-
regulation by MLL fusions possibly contribute to the overex-
pression of the microRNA-17-92 cluster in MLL-rearranged 
leukemia. Moreover, microRNA-17-92 significantly increase 
cell viability, while inhibiting the apoptosis of HeLa (human 
cervix carcinoma) and 293T (human embryonal kidney) 
lineage cells and enhance proliferation of mouse normal 
bone marrow progenitor cells, resulting in the transforma-
tion of these cells by microRNA-17-92 and in cooperation 
with MLL fusions. This suggests that overexpression of the 
microRNA-17-92 cluster in MLL-rearranged leukemias is 
attributable to both DNA copy number amplification and 
direct up-regulation by MLL fusions. 
The control of microRNA expression in ALL is still poorly 
understood. Nonetheless, several experimental data indi-
cate that epigenetic regulation is an important mechanism 
guiding the regulation of microRNA expression in ALL. 
Recently, Li et al. (57) observed that histone modifications 
are involved in microRNA deregulation in human ALL cells. 
Using NALM-6 cells and primary leukemic cells, this group 
demonstrated that the silencing of the microRNA-22 gene 
in all cells is associated with the accumulation of histone 
modifications in its promoter element, independent of DNA 
methylation. microRNA-22 is frequently down-regulated 
MicroRNAs in normal hematopoiesis and in T-ALL 625
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